Radford MG, Donadio JV, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy[J]. J Am Soc Nephrol, 1997, 8(2):199-207.
[2]
Bartosik LP, Lajoie G, Sugar L, et al. Predicting progression in IgA nephropathy [J]. Am J Kidney Dis, 2001, 38(4):728-735.
[3]
Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics [J]. Kidney Int, 2006, 69(2):21-31.
[4]
Huang CL, Shen S, Ma Q,et al. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis [J]. Nephrol Dial Transplant, 2014,29(2):313-324.
[5]
Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix [J].J Histochem Cytochem,2012,12(60):976-986.
[6]
Giunti S, Barutta F, Perin PC, et al. Targeting the MCP-1/CCR2 system in diabetic kidney disease [J]. Curr Vasc Pharmacol, 2010,8(6):849-860.
[7]
Michael Z, Eric G, Neilson. Mechanisms of Tubulointerstitial Fibrosis[J]. JASN,2010,11(21):1819-1834.
[8]
Strutz FM. EMT and proteinuria as progression factors[J]. Kidney Int, 2009,75:475-481.
[9]
Van Buren PN,Toto R. Current update in the management of diabetic nephropathy[J].Current Diabetes Reviews, 2013, 9(1):62-77.
[10]
Stojiljkovic L,Behnia R. Role of rennin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials[J]. Curr Pharm Des,2007, 13(13):1335-1345.
[11]
Liu Y, Zhou D, Xiao X, et al. Losartan preserves glomerular basement membrane anionic charge sites in a rat model of nephropathy [J]. J Nephrol,2013, 26(4):660-666.
[12]
Mizuno M, Sada T, Kato M, et al. The effect of angiotensin II receptor blockade an end-stage renal failure model of type 2 diabetes [J]. J Cardiovasc Pharmacol, 2006, 48(4):135-142.
